All In Biotech

Drug Trial Radar · NCT00758524

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 628 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

628

Actual

Start

Sep 11, 2008

Primary completion

Jul 2, 2009

Study completion Jul 2, 2009

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.

Conditions

  • Essential Hypertension

Interventions

  • LCI699Drug

    LCI699 oral capsules

  • EplerenoneDrug

    Eplerenone oral capsules

  • LCI699-matching PlaceboDrug

    LCI699-matching placebo oral capsules

  • Eplerenone-matching PlaceboDrug

    Eplerenone-matching placebo oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood Pressure (OBP)Time frame: Baseline, Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Pharmaceuticals

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.